Roche Announces Results of EMPACTA Study for Chugai’s Actemra for the Treatment of COVID-19
2020-09-18 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, September 18, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today regarding results of EMPACTA study for Actemra ® /RoActemra ® [generic name: tocilizumab (genetical recombination)] for the treatment of COVID-19. Actemra is a humanized anti-human IL-6 receptor monoclonal antibody created by Chugai. Please refer to the link below for details of the press release: Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia https://www.roche.com/investors/updates/inv-update-2020-09-18.htm Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗